Betta Pharmaceuticals Co., Ltd.

Shenzhen Stock Exchange 300558.SZ

Betta Pharmaceuticals Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 66.72

Betta Pharmaceuticals Co., Ltd. Price to Earnings Ratio (P/E) is 66.72 on January 27, 2025, a 38.09% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Betta Pharmaceuticals Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 68.58 on December 04, 2024, which is 2.79% above the current Price to Earnings Ratio (P/E).
Betta Pharmaceuticals Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 36.11 on July 23, 2024, which is -45.88% below the current Price to Earnings Ratio (P/E).
Betta Pharmaceuticals Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 50.14.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shenzhen Stock Exchange: 300558.SZ

Betta Pharmaceuticals Co., Ltd.

CEO	Dr. Lieming Ding
IPO Date	Nov. 9, 2016
Location	China
Headquarters	No. 355, Xingzhong Road
Employees	1,961
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Composite Materials Drugstores & Retail Pharmacies

Description

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.

Key trends

Past 5 years